Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by gregoooon Mar 01, 2013 11:17am

248 Views

Post# 21062157

BWN MD&A

I see from the BWN financials posted yesterday that the next well they are going to drill is the Flami #2 as soon as they can get a drilling rig etc and then possibly workover the Mani well.

No mention of the Canaguay #2.

Production Canaguay#1 550 bopd gross-so net 135

Flami #1 500 bopd gross-so net 235 until payout.

SMQ the same so approx. 370 bopd

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale